BTK Inhibitors Provide Option for CLL Patients With Severe Renal Dysfunction
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
BTK inhibitors have proven to be a powerful tool in CLL treatment and have replaced chemoimmunotherapy as the preferred first-line treatment.
A study presented at the 2023 ASH Conference, provided additional evidence for the healthy deployer effect, this time in individuals with non-Hodkin lymphoma.
Has cancer-directed therapy changed patterns of the incidence and risk of cancer-associated thrombosis (CAT) at the VA?
Could high levels of the chemokine TARC produced in tumor cells in classic Hodgkin lymphoma help predict the malignancy?
Chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) are the most common forms of adult leukemia. More than 13,000 veterans have the diagnosis, which is associated with the toxic exposures included in the Pact Act, according to the VA.